Aligos Therapeutics, Inc. (ALGS)
| Market Cap | 673.65M |
| Revenue (ttm) | 2.46M |
| Net Income (ttm) | -125.21M |
| Shares Out | 39.52M |
| EPS (ttm) | -4.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,783 |
| Open | 15.90 |
| Previous Close | 15.84 |
| Day's Range | 15.73 - 16.13 |
| 52-Week Range | 12.82 - 37.51 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 34.75 (+119.7%) |
| Est. Earnings Date | Nov 4, 2021 |
About ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 34.75, which is an increase of 119.66% from the latest price.
News
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
Raised $83.6 million in gross proceeds from common stock offering STOPS™ and CAM programs: initial data presented at conferences, dosing in 2 nd CHB cohorts ongoing Clinical trial application filed for...
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...
Aligos Therapeutics Raises $84M Via Equity At 7% Discount
Aligos Therapeutics Inc (NASDAQ: ALGS) has priced a previously announced underwritten public offering of 4.4 million shares at $19 per share, representing a discount of 7% from the last close price of $...
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stoc...
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of commo...
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of...
-Five scientific posters to be presented at upcoming EASL ILC meeting - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluate...
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at ...
Subjects experienced a 2.9 log 10 IU/mL mean reduction in HBV DNA levels after 14 days' dosing with 100 mg ALG-000184
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unm...
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
Advancement of Aligos' drug candidates continues to be on track Advancement of Aligos' drug candidates continues to be on track
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chron...
Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market ...
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatit...
The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on R...
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...
Aligos (ALGS) in Focus: Stock Moves 5.6% Higher
Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Ol...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement...
Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...
Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research
SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therap...
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...
Aligos Therapeutics stock rallies out of the gate, then pulls back
Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m.
Aligos Therapeutics Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its common stoc...